Q-omics provides the consensus-scored TRBV29OR9-2 profile across patient tissues and cancer cell-line models. TRBV29OR9-2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, TRBV29OR9-2 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, TRBV29OR9-2 RNA expression shows 10,014 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight THYM, STAD, and ESCA as cancer lineages where TRBV29OR9-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV29OR9-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV29OR9-2 survival associations across molecular data types. TRBV29OR9-2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV29OR9-2 RNA expression–survival associations across cancer types. High TRBV29OR9-2 expression shows unfavorable associations in THYM, ACC, LUSC, UCEC, KICH and LUAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for TRBV29OR9-2 RNA expression.
This table summarizes TRBV29OR9-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV29OR9-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV29OR9-2 shows lower tumor expression in HNSC and higher tumor expression in STAD, LUSC, LUAD, ESCA and COAD. The STAD box plot shows higher TRBV29OR9-2 RNA expression in tumor versus normal tissue (log2 FC = +0.727, t-test p = .002).
This table shows molecular features associated with TRBV29OR9-2 in patient tissues and cancer cell lines. In patient samples, TRBV29OR9-2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
